Search

Your search keyword '"Cabibbo, A"' showing total 180 results

Search Constraints

Start Over You searched for: Author "Cabibbo, A" Remove constraint Author: "Cabibbo, A" Topic medicine.disease Remove constraint Topic: medicine.disease
180 results on '"Cabibbo, A"'

Search Results

1. Recalibrating survival prediction among patients receiving trans‐arterial chemoembolization for hepatocellular carcinoma

2. Surveillance for hepatocellular carcinoma with a 3-months interval in 'extremely high-risk' patients does not further improve survival

3. Hepatotoxicity of systemic therapies for unresectable hepatocellular carcinoma

4. Hepatocellular carcinoma with macrovascular invasion: multimodality imaging features for the diagnosis

5. The quest for precision oncology with immune checkpoint inhibitors for hepatocellular carcinoma

6. Overview of Prognostic Systems for Hepatocellular Carcinoma and ITA.LI.CA External Validation of MESH and CNLC Classifications

7. Pattern of macrovascular invasion in hepatocellular carcinoma

8. Changes in hepatocellular carcinoma aggressiveness characteristics with an increase in tumor diameter

9. Nonalcoholic steatohepatitis in hepatocarcinoma: new insights about its prognostic role in patients treated with lenvatinib

10. Monofocal hepatocellular carcinoma: How much does size matter?

11. Time-Varying mHAP-III Is the Most Accurate Predictor of Survival in Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization

12. Hepatocellular carcinoma recurrence after direct-acting antiviral therapy: An individual patient data meta-analysis

13. Adverse events as potential predictive factors of activity in patients with advanced hepatocellular carcinoma treated with lenvatinib

14. First-Line Immune Checkpoint Inhibitor-Based Sequential Therapies for Advanced Hepatocellular Carcinoma: Rationale for Future Trials

15. Prognostic Role of Blood Eosinophil Count in Patients with Sorafenib-Treated Hepatocellular Carcinoma

16. Validation and refinement of PROSASH model using the neutrophil‐to‐lymphocyte ratio in patients with HCC receiving sorafenib

18. Assessing the impact of COVID-19 on liver cancer management (CERO-19)

19. Long-term evolution of LI-RADS observations in HCV-related cirrhosis treated with direct-acting antivirals

20. Antiviral therapy in the palliative setting of HCC (BCLC-B and -C)

21. Management of liver disease in Italy after one year of the SARS-CoV-2 pandemic: a web-based survey

22. Real-Life Clinical Data of Cabozantinib for Unresectable Hepatocellular Carcinoma

23. Liver and cardiovascular mortality after hepatitis C virus eradication by DAA: Data from RESIST-HCV cohort

24. Are radiological endpoints surrogate outcomes of overall survival in hepatocellular carcinoma treated with transarterial chemoembolization?

25. Outcomes of hepatocellular carcinoma patients treated with sorafenib: a meta-analysis of Phase III trials

26. Progression-Free Survival Early Assessment Is a Robust Surrogate Endpoint of Overall Survival in Immunotherapy Trials of Hepatocellular Carcinoma

27. Correction to: Prognostic Role of Blood Eosinophil Count in Patients with Sorafenib-Treated Hepatocellular Carcinoma

28. SARS-CoV-2 infection in patients with a normal or abnormal liver

29. Circadian rhythm of COPD symptoms in clinically based phenotypes. Results from the STORICO Italian observational study

30. The concept of therapeutic hierarchy for patients with hepatocellular carcinoma: A multicenter cohort study

31. Sicily Network for Liver Cancer: A Multidisciplinary Network Model for the Management of Primary Liver Tumors

32. Direct-acting antiviral agents and risk of Hepatocellular carcinoma: Critical appraisal of the evidence

33. Effect of direct-acting antivirals on future occurrence of hepatocellular carcinoma in compensated cirrhotic patients

34. Hepatocellular carcinoma recurrence in patients with curative resection or ablation: impact of HCV eradication does not depend on the use of interferon

35. Treatment of Hepatocellular Carcinoma with Immune Checkpoint Inhibitors and Applicability of First-Line Atezolizumab/Bevacizumab in a Real-Life Setting

36. Patients with advanced hepatocellular carcinoma need a personalized management: A lesson from clinical practice

37. Direct-acting antivirals and hepatocellular carcinoma in chronic hepatitis C: A few lights and many shadows

38. Metabolic disorders across hepatocellular carcinoma in Italy

39. Ten years of sorafenib in hepatocellular carcinoma: Are there any predictive and/or prognostic markers?

40. Hyperintense nodule-in-nodule on hepatobiliary phase arising within hypovascular hypointense nodule: Outcome and rate of hypervascular transformation

41. Direct-acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients

42. Consensus statements on vaccination in patients with haemophilia—Results from the Italian haemophilia and vaccinations (HEVA) project

43. Pattern of macrovascular invasion in patients with hepatocellular carcinoma influences treatment and outcome

44. Hepatic decompensation is the major driver of death in HCV-infected cirrhotic patients with successfully treated early hepatocellular carcinoma

45. A meta-analysis of single HCV-untreated arm of studies evaluating outcomes after curative treatments of HCV-related hepatocellular carcinoma

46. Curative therapies are superior to standard of care (transarterial chemoembolization) for intermediate stage hepatocellular carcinoma

47. OC.04.3 FIRST-LINE IMMUNE CHECKPOINT INHIBITOR-BASED SEQUENTIAL THERAPIES FOR ADVANCED HEPATOCELLULAR CARCINOMA: A RATIONALE FOR FUTURE TRIALS

48. Laser ablation is superior to TACE in large-sized hepatocellular carcinoma: A pilot case-control study

49. Utility of Tumor Burden Score to Stratify Prognosis of Patients with Hepatocellular Cancer: Results of 4759 Cases from ITA.LI.CA Study Group

50. Clinical outcomes with long-term sorafenib treatment of patients with hepatocellular carcinoma: A multicenter real-life study

Catalog

Books, media, physical & digital resources